



16th July 2025

The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001
Scrip Code: 500674

The Secretary
The National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra East,
Mumbai 400 050
Symbol: SANOFI

Sub: Outcome of Board Meeting of the Company held on Wednesday, 16th July 2025

Dear Sir / Madam,

We wish to inform you that the Board of Directors, at its meeting held today i.e., Wednesday, 16th July 2025, inter-alia considered and approved the following matters:

1. With reference to our letter dated 9th April 2025, informing about the cessation of Mr. Rodolfo Hrosz as the Managing Director of the Company with effect from the close of business hours on 30th April 2025 and pursuant to the requirements of Regulation 26A and 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations, 2015"), we wish to inform you that upon the recommendation of the Nomination and Remuneration Committee and subject to approval of the Shareholders, the Board of Directors have approved the appointment of Mr. Rachid Ayari (DIN: 10408699) as the Interim Managing Director of the Company, in addition to his current role as the Chief Financial Officer of the Company, for a term of 6 months from 21st July 2025 to 20th January 2026 or until a Permanent Managing Director is appointed, whichever is earlier.
2. In compliance with Regulation 30 of SEBI Listing Regulations, 2015, we wish to inform you that, upon the recommendation of the Nomination and Remuneration Committee, the Board of Directors have appointed Mr. Aniket Raje as the Head of Regulatory Affairs of the Company, with effect from 1st August 2025.
3. The Board of Directors approved an exclusive distribution and promotion agreement between the Company and Emcure Pharmaceuticals Limited for an initial period of 5 years on such terms and conditions as agreed between the Parties, effective immediately. A press release in this regard is enclosed.



The information required in terms of Regulation 30 read with Schedule III of the Listing Regulations and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 is enclosed as 'Annexure-I' to this letter

The meeting of Board of Directors commenced at 3:15 p.m. and concluded at 5 p.m.

Please take the above information on record.

Thanking you,

Yours faithfully
For **Sanofi India Limited**

Arjun Thakkar
Company Secretary and Compliance Officer
Membership No.: A22654

Encl:

- 1) Annexure - I*
- 2) Press Release*

Information as required under Regulation 30 read with Schedule III - Para A of Part A of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

1. Appointment of Mr. Rachid Ayari (DIN: 10408699) as the Interim Managing Director of the Company:

Sr. No.	Particulars	Details
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Appointment of Mr. Rachid Ayari (DIN: 10408699) as the Interim Managing Director of the Company, in addition to his current role as the Chief Financial Officer of the Company.
2.	Date of appointment / re-appointment / cessation (as applicable) & term of appointment;	Appointment for a term of 6 months from 21 st July 2025 to 20 th January 2026 or until a Permanent Managing Director is appointed, whichever is earlier. There shall be no change in the terms and conditions of his appointment.
3.	Brief profile (in case of appointment)	With over 8 years of experience at Sanofi, following a 16-year tenure at Pfizer, Mr. Rachid Ayari bring a wealth of knowledge in major finance fields and a diverse international background, having worked across various countries as CFO from North Africa to Russia & Central Asia and finally India. His expertise extends to financial management, working closely with cross-functional teams, and ensuring compliance with regulatory and corporate standards.
4.	Disclosure of relationships between directors (in case of appointment of a director).	Mr. Rachid Ayari is not related to any of the Directors of the Company personally, financially or otherwise and is not debarred or disqualified from being appointed or continuing as director of any company by SEBI / Ministry of Corporate Affairs or any such statutory authority.

2. Appointment of Mr. Aniket Raje as the Head of Regulatory Affairs of the Company:

Sr. No.	Particulars	Details
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Appointment of Mr. Aniket Raje as the Head of Regulatory Affairs of the Company
2.	Date of appointment / re-appointment / cessation (as applicable) & term of appointment;	<ul style="list-style-type: none"> - Appointment with effect from 1st August 2025 - Term of Appointment: Whole-time Employment
3.	Brief profile (in case of appointment)	<p>With over 21 years of experience in the technical departments in the Pharmaceutical Industry, Mr. Aniket Raje possesses vast experience in product registration and life-cycle management, internal and external stakeholder management and leadership roles. He was previously associated with Sanofi Healthcare India Private Limited, a Sanofi Group Company, as the Head Regulatory-Vaccines And Rare Disease.</p> <p>He has completed his Masters (M.Sc.) in Biochemistry (Clinical) from G.S. Medical College and K.E.M Hospital (Mumbai University, India).</p>
4.	Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable



Press Release

India

Sanofi India Limited and Emcure announce exclusive distribution partnership to broaden reach of Sanofi's Oral Anti-diabetic drugs

Mumbai, July 16, 2025. The Board of Directors of Sanofi India Limited ("SIL") today approved an exclusive distribution and promotion agreement between SIL and Emcure Pharmaceuticals Limited ("Emcure") for SIL's oral anti-diabetic (OAD) products in India, effective immediately.

Emcure will exclusively distribute and promote the Company's OAD range of products that include well-established brands like Amaryl® and Cetapin®.

While SIL will continue to own and manufacture these brands across Sanofi's plants in India and internationally, Emcure will leverage its strengths to engage healthcare professionals and expand reach of these therapeutic solutions for patients who need them across all of India.

There will be no people transition from SIL to Emcure in this arrangement.

Eric Mansion

General Manager – Pharma, Southeast Asia and India & MCO Lead, Sanofi

"Over 100 millionⁱ Indians are living with type 2 diabetes and its complexities in India. Of these, >60% peopleⁱⁱ are living with uncontrolled blood sugar levels and have a higher risk of developing complications, over a long period of time. Sanofi's commitment to improving their lives and helping them manage their diabetes better remains unwavering. With Emcure's wide and deeply penetrated presence across India, we're confident of tapping into the full growth potential of our best-in-class & industry-leading OADs Amaryl® and Cetapin®. This partnership will truly benefit both – the patients who need them and the HCPs who trust and prescribe them."

Mr. Satish Mehta

Chief Executive Office and Managing Director, Emcure

"At Emcure, we are committed to improving patient access to high-quality therapies. With our strong distribution network in India, Sanofi's trusted oral anti-diabetic medicines will be available to more patients who need them. This collaboration complements our existing diabetes portfolio, creating a comprehensive offering for the millions living with diabetes and supporting better diabetes care across the country."

Sanofi in India

Present in India for nearly seven decades, Sanofi has earned the trust of customers and stakeholders for its commitment to promoting health. As Sanofi chases the miracles of science to improve people's lives, it continues to engage across the entire health spectrum from prevention with vaccines to wellness, treatment, patient support & capacity building.

Sanofi's India Charitable Access Program (InCAP) is the country's longest running humanitarian program providing free treatment to people afflicted with Lysosomal Storage Disorders. Sanofi conducts clinical trials in India, so that the country can have quicker access to the latest from the company's global pipeline. Sanofi India's world-class manufacturing site in Goa produces for people in India and 60+ other countries. Sanofi has located one of its four global talent hubs in Hyderabad, India, from where wide range of services are provided globally.

Recognized by the 'Top® Employers Institute' – a global authority that honours excellence in people practices since 2019, Sanofi's local entities include Sanofi India Limited (SIL – listed entity), and Sanofi Healthcare India Pvt. Ltd. (SHIPL).

For more information, visit: www.sanofi.com/en/in, [LinkedIn](#) and [Twitter](#).

About Emcure

Emcure Pharmaceuticals Ltd. (EPL) is a leading Indian pharma company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. Known for its commitment to innovation, quality, and patient-centricity, Emcure is an R&D driven company that develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Established in 1981, EPL is ranked as the 12th largest pharma company in India in terms of Domestic Sales for MAT June 2024. Emcure is present in 70+ countries globally including Europe and Canada.

Media Relations

Vinifer Gandhi | vinifer.gandhi@sanofi.com || Naveen Soni | naveen.soni@emcure.com

ⁱ Anjana RM, Unnikrishnan R, Deepa M, Pradeepa R, Tandon N, Das AK, Joshi S, Bajaj S, Jabbar PK, Das HK, Kumar A, Dhandhanika VK, Bhansali A, Rao PV, Desai A, Kalra S, Gupta A, Lakshmy R, Madhu SV, Elangovan N, Chowdhury S, Venkatesan U, Subashini R, Kaur T, Dhaliwal RS, Mohan V; ICMR-INDIAB Collaborative Study Group. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). *Lancet Diabetes Endocrinol.* 2023 Jul;11(7):474-489.

ⁱⁱ LANDMARC study final publication: Das AK, Kalra S, Joshi S, Mithal A, Kumar KMP, Unnikrishnan AG, Thacker H, Sethi B, Chowdhury S, Sugumaran A, Satpathy A, Gadekar A, Menon SK, Neogi R, Chodankar D, Trivedi C, Wangnoo SK, Zargar AH, Rais N; LANDMARC study group. The Longitudinal Nationwide study on Management And Real-world outcomes of diabetes in India over 3 years (LANDMARC trial). *Endocrinol Diabetes Metab.* 2023 Sep;6(5):e422.